A Phase 3 trial of niraparib in combination with an anti-PD-1 antibody in comparison to anti-PD-1 alone in patients with advanced NSCLC and high levels of PDL-1 tumor expression.
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Niraparib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Apr 2017 New trial record